The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characteristics of patients with resectable early-stage non–small cell lung cancer treated with neoadjuvant chemoimmunotherapy or surgery ± adjuvant therapy.
 
Pragya Rai
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
Research Funding - Merck Sharp & Dohme
 
Yu-Han Kao
Employment - Merck
Stock and Other Ownership Interests - Merck; Merck
 
Ashwini Arunachalam
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Jeffrey Thompson
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
Research Funding - Merck Sharp & Dohme
 
Ayman Samkari
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
Research Funding - Merck Sharp & Dohme
 
Jay Lee
Stock and Other Ownership Interests - Moderna Therapeutics
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Foundation Medicine; Genentech/Roche; Lilly; Merck; Natera; Novartis; Regeneron
Speakers' Bureau - AstraZeneca; Bristol Myers Squibb Foundation; Genentech/Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis; Tempus AI, Inc.
Patents, Royalties, Other Intellectual Property - UCLA Patents
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Genentech/Roche; Merck; Regeneron
(OPTIONAL) Uncompensated Relationships - Genentech/Roche; Novartis